| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| Breast Cancer |
| 366- | AgNPs, | Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis |
| - | in-vitro, | BC, | MCF-7 |
| - | in-vitro, | BC, | BT474 |
| - | Trial, | BC, | NA |
| 2738- | BetA, | Betulinic Acid Suppresses Breast Cancer Metastasis by Targeting GRP78-Mediated Glycolysis and ER Stress Apoptotic Pathway |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | BT549 | - | in-vivo, | NA, | NA |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 2304- | CUR, | Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1α inhibition |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Pca, | PC3 | - | in-vitro, | Nor, | HEK293 |
| 1446- | Deg, | Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells |
| - | in-vitro, | BC, | 4T1 |
| 951- | DHA, | Docosahexaenoic Acid Attenuates Breast Cancer Cell Metabolism and the Warburg Phenotype by Targeting Bioenergetic Function |
| - | in-vitro, | BC, | BT474 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | Nor, | MCF10 |
| 1056- | EGCG, | EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1α and NFκB, and VEGF expression |
| - | vitro+vivo, | BC, | E0771 |
| 668- | EGCG, | The Potential Role of Epigallocatechin-3-Gallate (EGCG) in Breast Cancer Treatment |
| - | Review, | BC, | MCF-7 | - | Review, | BC, | MDA-MB-231 |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 949- | FIS, | ATAGJ, | Cisplatin, | Ai-Tong-An-Gao-Ji and Fisetin Inhibit Tumor Cell Growth in Rat CIBP Models by Inhibiting the AKT/HIF-1α Signaling Pathway |
| - | in-vivo, | BC, | Walker256 | - | in-vitro, | BC, | Walker256 |
| 960- | HNK, | Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth |
| - | vitro+vivo, | BC, | MCF-7 | - | vitro+vivo, | BC, | MDA-MB-231 |
| 1243- | LA, | Lactobacilli Modulate Hypoxia-Inducible Factor (HIF)-1 Regulatory Pathway in Triple Negative Breast Cancer Cell Line |
| - | in-vitro, | BC, | MDA-MB-231 |
| 1203- | MSM, | Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways |
| - | vitro+vivo, | BC, | MDA-MB-231 |
| 968- | OA, | Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization |
| - | vitro+vivo, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MBT-2 |
| 959- | PACs, | Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | BC, | MDA-MB-231 |
| 4936- | PEITC, | PEITC treatment suppresses myeloid derived tumor suppressor cells to inhibit breast tumor growth |
| - | in-vivo, | BC, | MDA-MB-231 |
| 4941- | PEITC, | PEITC: A resounding molecule averts metastasis in breast cancer cells in vitro by regulating PKCδ/Aurora A interplay |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | MDA-MB-231 |
| 2303- | QC, | doxoR, | Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1α in tumor and normal cells |
| - | in-vitro, | BC, | 4T1 | - | in-vivo, | NA, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF-7 |
| 3064- | RES, | Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation |
| - | in-vitro, | CRC, | HT-29 | - | in-vitro, | BC, | T47D | - | in-vitro, | Lung, | LLC1 |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 1210- | SANG, | Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1α pathways in breast cancer |
| - | in-vitro, | BC, | NA |
| 1732- | SFN, | Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | BC, | SUM159 | - | in-vivo, | NA, | NA |
| 3115- | VitC, | The NF-κB Transcriptional Network Is a High-Dose Vitamin C-Targetable Vulnerability in Breast Cancer |
| - | in-vitro, | BC, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:4 Cells:% prod#:% Target#:143 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid